Spots Global Cancer Trial Database for patidegib
Every month we try and update this database with for patidegib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC | NCT04155190 | Recurrent Basal... | Patidegib Topic... Patidegib Topic... | 18 Years - | Sol-Gel Technologies, Ltd. | |
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients | NCT02762084 | Basal Cell Nevu... | Patidegib Vehicle gel | 18 Years - 85 Years | PellePharm, Inc. | |
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC | NCT04155190 | Recurrent Basal... | Patidegib Topic... Patidegib Topic... | 18 Years - | Sol-Gel Technologies, Ltd. | |
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) | NCT04308395 | Basal Cell Nevu... | Patidegib Topic... | 18 Years - | Sol-Gel Technologies, Ltd. | |
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome) | NCT03703310 | Basal Cell Nevu... | Patidegib Topic... Patidegib Topic... | 18 Years - | PellePharm, Inc. | |
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas | NCT02828111 | Basal Cell Carc... | Patidegib Vehicle gel | 18 Years - 85 Years | PellePharm, Inc. | |
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas | NCT02828111 | Basal Cell Carc... | Patidegib Vehicle gel | 18 Years - 85 Years | PellePharm, Inc. | |
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) | NCT04308395 | Basal Cell Nevu... | Patidegib Topic... | 18 Years - | Sol-Gel Technologies, Ltd. |